understanding the trial with idelalisib and rituximab
Published 4 years ago • 62 plays • Length 4:11Download video MP4
Download video MP3
Similar videos
-
2:09
dr. furman on the efficacy and safety of idelalisib and rituximab for previously treated cll
-
2:52
updated analysis of phase iii trial of idelalisib combined with bendamustine and rituximab in cll
-
2:48
pi3k/anti-cd20 therapy for relapsed/refractory cll
-
1:49
trial results of idelalisib with bendamustine and rituximab in cll
-
4:51
idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory cll
-
3:35
trial of ibrutinib with bendamustine and rituximab in cll: results and study design
-
0:41
reviewing key points from the phase iii murano trial in cll
-
3:43
cll: clinical data for rituximab/venetoclax
-
1:18
findings from the relevance trial in follicular lymphoma
-
1:05
current salvage therapy options for relapsed/refractory cll
-
3:04
follicular lymphoma: second-line therapy options
-
8:58
venetoclax plus rituximab in relapsed/refractory cll
-
1:55
phase 1b trial of idelalisib plus chemoimmunotherapy for relapsed/refractory cll
-
3:18
second interim phase 3 study of idelalisib /rituximab for relapsed chronic lymphocytic leukemia
-
2:09
understanding clinical trials - the oncology institute
-
4:52
3-year dfs in randomized trials of chemotherapy and her2-targeted therapy
-
2:07
side-effect of idelalisib and its use in chronic lymphocytic leukemia
-
9:05
acalabrutinib vs. rituximab combined with idelalisib or bendamustine for cll - asco 2022
-
20:43
venetoclax resistance: mechanisms and treatment options